Overview

Definitive QT Study With MT-8554

Status:
Completed
Trial end date:
2018-10-19
Target enrollment:
Participant gender:
Summary
This is a study to definitively assess the effects of MT 8554, adjusted for placebo, on the change of the QT interval corrected for heart rate (HR) using the Fridericia formula (QTcF) from Baseline in healthy adult subjects
Phase:
Phase 1
Details
Lead Sponsor:
Mitsubishi Tanabe Pharma Development America, Inc.